Moderna Deferred Long Term Liab vs Common Stock Shares Outstanding Analysis

MRNA Stock  USD 42.86  1.35  3.25%   
Moderna financial indicator trend analysis is infinitely more than just investigating Moderna recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moderna is a good investment. Please check the relationship between Moderna Deferred Long Term Liab and its Common Stock Shares Outstanding accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Deferred Long Term Liab vs Common Stock Shares Outstanding

Deferred Long Term Liab vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moderna Deferred Long Term Liab account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Moderna's Deferred Long Term Liab and Common Stock Shares Outstanding is -0.29. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Moderna, assuming nothing else is changed. The correlation between historical values of Moderna's Deferred Long Term Liab and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Moderna are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Deferred Long Term Liab i.e., Moderna's Deferred Long Term Liab and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

-0.29
Relationship DirectionNegative 
Relationship StrengthInsignificant

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.
Most indicators from Moderna's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.2 B, whereas Issuance Of Capital Stock is forecasted to decline to about 43.7 M.
 2021 2022 2023 2024 (projected)
Interest Income18M200M405M425.3M
Net Interest Income18M200M363M381.2M

Moderna fundamental ratios Correlations

0.860.990.910.930.930.920.870.840.780.91-0.470.950.74-0.980.610.70.950.890.64-0.840.950.780.80.660.97
0.860.770.650.650.640.610.991.00.60.99-0.140.950.63-0.780.70.660.690.590.94-0.990.790.420.920.550.92
0.990.770.930.960.980.960.790.730.80.83-0.540.90.73-0.980.540.660.980.940.51-0.740.960.860.710.650.94
0.910.650.930.950.910.960.690.620.670.72-0.690.80.7-0.920.470.760.960.950.38-0.620.830.790.620.710.83
0.930.650.960.950.960.990.690.620.710.71-0.730.80.75-0.960.510.61.01.00.37-0.620.870.850.620.670.86
0.930.640.980.910.960.980.660.60.750.71-0.60.810.62-0.970.410.550.970.950.34-0.610.930.920.60.550.86
0.920.610.960.960.990.980.650.580.70.68-0.730.780.7-0.950.460.590.990.990.31-0.570.870.880.580.650.84
0.870.990.790.690.690.660.650.990.590.99-0.190.960.67-0.810.650.650.720.630.91-0.990.80.420.950.60.93
0.841.00.730.620.620.60.580.990.550.98-0.140.920.61-0.760.670.630.660.560.95-0.990.740.360.940.520.89
0.780.60.80.670.710.750.70.590.550.66-0.220.750.72-0.740.470.660.740.690.39-0.560.820.70.480.640.76
0.910.990.830.720.710.710.680.990.980.66-0.180.980.66-0.830.70.70.750.660.9-0.980.850.50.910.60.95
-0.47-0.14-0.54-0.69-0.73-0.6-0.73-0.19-0.14-0.22-0.18-0.24-0.50.55-0.21-0.29-0.69-0.770.090.12-0.3-0.52-0.17-0.41-0.32
0.950.950.90.80.80.810.780.960.920.750.98-0.240.71-0.90.670.710.830.750.79-0.920.930.640.870.670.99
0.740.630.730.70.750.620.70.670.610.720.66-0.50.71-0.680.630.590.750.740.48-0.610.620.510.510.840.72
-0.98-0.78-0.98-0.92-0.96-0.97-0.95-0.81-0.76-0.74-0.830.55-0.9-0.68-0.47-0.62-0.97-0.93-0.520.76-0.94-0.8-0.78-0.62-0.94
0.610.70.540.470.510.410.460.650.670.470.7-0.210.670.63-0.470.60.520.490.68-0.620.520.440.410.570.67
0.70.660.660.760.60.550.590.650.630.660.7-0.290.710.59-0.620.60.630.590.54-0.610.610.450.540.730.67
0.950.690.980.961.00.970.990.720.660.740.75-0.690.830.75-0.970.520.630.990.41-0.650.890.850.650.680.88
0.890.590.940.951.00.950.990.630.560.690.66-0.770.750.74-0.930.490.590.990.3-0.550.830.850.550.680.82
0.640.940.510.380.370.340.310.910.950.390.90.090.790.48-0.520.680.540.410.3-0.940.540.120.850.380.73
-0.84-0.99-0.74-0.62-0.62-0.61-0.57-0.99-0.99-0.56-0.980.12-0.92-0.610.76-0.62-0.61-0.65-0.55-0.94-0.75-0.36-0.95-0.52-0.89
0.950.790.960.830.870.930.870.80.740.820.85-0.30.930.62-0.940.520.610.890.830.54-0.750.830.720.590.95
0.780.420.860.790.850.920.880.420.360.70.5-0.520.640.51-0.80.440.450.850.850.12-0.360.830.280.470.7
0.80.920.710.620.620.60.580.950.940.480.91-0.170.870.51-0.780.410.540.650.550.85-0.950.720.280.460.84
0.660.550.650.710.670.550.650.60.520.640.6-0.410.670.84-0.620.570.730.680.680.38-0.520.590.470.460.67
0.970.920.940.830.860.860.840.930.890.760.95-0.320.990.72-0.940.670.670.880.820.73-0.890.950.70.840.67
Click cells to compare fundamentals

Moderna Account Relationship Matchups

Moderna fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.6B7.3B24.7B25.9B18.4B19.3B
Total Current Liabilities143.1M4.4B9.1B4.9B3.0B2.4B
Total Stockholder Equity1.2B2.6B14.1B19.1B13.9B14.5B
Other Liab139.1M179.3M691M808M929.2M975.7M
Net Tangible Assets1.2B2.6B14.1B19.1B22.0B23.1B
Retained Earnings(1.5B)(2.2B)10.0B18.3B13.6B14.3B
Accounts Payable7.1M18M302M487M520M546M
Cash235.9M2.6B6.8B3.2B2.9B1.8B
Net Receivables16.3M1.4B3.2B1.4B892M848.5M
Other Current Assets887.9M252M607M1.4B643M462.8M
Total Liab414.6M4.8B10.5B6.7B4.6B3.1B
Total Current Assets1.3B6.3B16.1B13.4B10.3B5.6B
Common Stock33K34K40K(857M)(771.3M)(732.7M)
Other Current Liab5.1M4.3B1.5B2.2B1.8B1.2B
Common Stock Shares Outstanding330.8M381.3M431M416M382M346.5M
Short Long Term Debt Total132.4M207.3M916M1.2B1.2B1.3B
Property Plant And Equipment Net287.9M387M1.4B2.1B2.7B2.8B
Current Deferred Revenue63.3M3.9B6.3B2.0B568M539.6M
Net Debt(103.5M)(2.6B)(6.8B)(3.2B)(1.7B)(1.7B)
Non Current Assets Total326.4M1.0B8.6B12.4B8.1B4.3B
Non Currrent Assets Other(121.5M)13M46M946M523M549.2M
Other Assets12.7M742.0M7.4B1.9B2.2B1.6B
Cash And Short Term Investments1.3B4.6B10.7B9.9B8.6B5.3B
Short Term Investments867.1M2.0B3.9B6.7B5.7B3.0B
Liabilities And Stockholders Equity1.6B7.3B24.7B25.9B18.4B11.3B
Non Current Liabilities Total271.5M387M1.4B1.8B1.6B868.0M
Capital Surpluse2.7B4.8B4.2B1.2B1.3B2.4B
Capital Lease Obligations132.4M207.3M916M1.0B1.2B1.3B
Other Stockholder Equity2.7B4.8B4.2B1.2B371M352.5M
Long Term Investments160.0M638.8M6.8B8.3B4.7B2.9B
Accumulated Other Comprehensive Income1.8M3M(24M)(370M)(123M)(116.9M)
Non Current Liabilities Other138K386.6M1.4B135M256M299.3M
Short Term Debt67.7M30M1.1B244M25M23.8M
Property Plant Equipment287.9M387.1M1.4B2.1B2.5B2.6B
Net Invested Capital1.2B2.6B14.1B19.1B13.9B8.1B
Property Plant And Equipment Gross287.9M387.1M1.7B2.1B3.1B3.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.85)
Earnings Share
(5.81)
Revenue Per Share
13.275
Quarterly Revenue Growth
0.017
Return On Assets
(0.1)
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.